Geminin overexpression induces mammary tumors via suppressing cytokinesis.

Zannel Blanchard; Rohit Malik; Nicole Mullins; Christine Maric; Hugh Luk; David Horio; Brenda Hernandez; Jeffrey Killeen; Wael M. ElShamy

doi:10.18632/oncotarget.363

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Geminin overexpression induces mammary tumors via suppressing cytokinesis.

Zannel Blanchard, Rohit Malik, Nicole Mullins, Christine Maric, Hugh Luk, David Horio, Brenda Hernandez, Jeffrey Killeen and Wael M. ElShamy _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2011; 2:1011-1027. https://doi.org/10.18632/oncotarget.363

Metrics: PDF 3406 views | HTML 5550 views | ?

Abstract

Zannel Blanchard^*, Rohit Malik^*, Nicole Mullins, Christine Maric, Hugh Luk, David Horio, Brenda Hernandez, Jeffrey Killeen and Wael M. ElShamy

¹Cancer Institute and Department of Biochemistry, University of Mississippi Medical Center, 2500 N. State St., G651-6, Jackson, MS 39216

^*Denotes equal contribution

Received: November 28, 2011; Accepted: December 9, 2011; Published: December 17, 2011;

Keywords:Geminin overexpression induces mammary tumors

Correspondence:

Wael M. ElShamy, email:

Abstract

Aneuploidy plays an important role in the development of cancer. Here, we uncovered an oncogenic role for geminin in mitotic cells. In addition to chromatin, tyrosine phosphorylated geminin also localizes to centrosome, spindle, cleavage furrow and midbody during mitosis. Geminin binding to Aurora B prevents its binding to INCENP, and thus activation leading to lack of histone H3-(serine 10) phosphorylation, chromosome condensation failure, aborted cytokinesis and the formation of aneuploid, drug resistance cells. Geminin overexpressing human mammary epithelial cells form aneuploid, aggressive tumors in SCID mice. Geminin is overexpressed in more than half of all breast cancers analyzed. The current study reveals that geminin is a genuine oncogene that promotes cytokinesis failure and production of aneuploid, aggressive breast tumors when overexpressed and thus a worthy therapeutic target (oncotarget) for aggressive breast cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 363

Publication Alerts

Post-Publication Promotion

Research Papers:

Geminin overexpression induces mammary tumors via suppressing cytokinesis.

Abstract